Nanomedicines for nervous system diseases

Abstract

The need for the development of nanomedicines for the treatment of degenerative and inflammatory diseases of the nervous system is of immediate importance. Nanoparticles are drug carriers that can specifically target diseased brain subregions and thus enhance therapeutic efficacy. Multifunctional nanoparticles delivering pharmaceutical agents serve a dual purpose: While they facilitate drug delivery they also provide imaging of cell dynamics and pharmacokinetic assessments. Polymer science and nanotechnology could be used to improve diagnostic and therapeutic outcomes. Despite their promise in combating disease, nanomedicines have yet to make their mark as broadly viable pharmaceuticals. The translation of nanoformulation technology for clinical therapeutic and diagnostic applications shows both real potential and inherent obstacles. However, safety concerns remain operative for their potential broad clinical implications, tempering any translational potential.